Dublin, Oct. 24, 2018 (GLOBE NEWSWIRE) -- The "Global TNF Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The Global TNF Inhibitors Market to grow at a CAGR of 9.58% during the period 2019-2023.

Global TNF Inhibitors Market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the key vendors operating in this market. The report covers the present scenario and the growth prospects of the TNF inhibitors market. To calculate the market size, the report considers the revenue generated from the application of TNF inhibitors in healthcare across the globe.

One trend affecting this market is the growing number of strategic alliances. At the present, biotech companies dominate the research area for drugs for tumor necrosis factor as they out-license the molecules or technology platforms to the bigger pharmaceutical companies.

According to the report, one driver influencing this market is the increasing prevalence of autoimmune disorders across the globe. The rising incidences of tumor necrosis factor cancer and growing prevalence of various autoimmune disorders such as RA, psoriasis, and Chron's disease is expected to fuel the demand for TNF immunology across the period of forecast.

Further, the report states that one challenge affecting this market is the growing advent of biosimilars. Vendors are increasingly focused on the development of biosimilars, which is expected to hinder the growth of the TNF inhibitors market.

Key questions answered in this report

• What will the market size be in 2023 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
  

Key vendors

• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• UCB

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 08: MARKET SEGMENTATION BY INDICATION

• Market segmentation by indication
• Comparison by indication
• TNF inhibitors for RA - Market size and forecast 2018-2023
• TNF inhibitors for psoriasis - Market size and forecast 2018-2023
• TNF inhibitors for IBD - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by indication

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• UCB

PART 14: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/xn4r93/global_tnf?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.